demonstrated a most simple outpatient technique of excising the sinus and cleaning out any tracts under local anaesthesia. Over the last six years I have used this method for almost a hundred patients and the rate of recurrence has been negligible. The procedure takes less than 10 minutes, only a dry dressing is required, and many patients return to work the following day. Most patients can then attend to their own dressings, and one or two follow-up visits to the clinic are all that is required before discharge. Instead of six inpatient days with the foam elastomer sponge those treated by the Lord® technique spend more like six minutes in the hospital.

K M DICKINSON
Victoria Hospital, Blackpool

Early thymectomy for myasthenia gravis

SIR,—I have long accepted the value of early thymectomy in myasthenia gravis and I therefore take interest Mr A E Kark's (6 September, p 593) and Mr C Grimshaw's (4 October, p 40) comments.

No one would deny that a less mutilating surgical procedure must benefit the patient (and the surgeon), but what we are seeing is the likelihood that anything less than a full exposure of the anterior mediastinum may result in a procedure which is less than a total thymectomy. The following case illustrates this.

A woman aged 41 underwent trans-sternal thymectomy for generalised myasthenia. A typical fleshy thymus gland weighing 10 g was removed. It must be stressed that the gland was clearly delineated and easily dissected in its entirety, and one would have been justified in assuming that the whole thymus had been removed. However, a final look round before closure revealed fatty masses on either side and extending into the lung hila. These were then dissected and also examined histologically. Section of the thymus revealed thymic tissue with areas of adipose tissue between lymphoid aggregates, germinal centers being very prominent. Sections of both lateral fatty masses revealed adipose tissue with fragments of thymic tissue similar to the histological features noted in the main thymus gland.

It is known that ectopic thymic tissue is not uncommon, the above findings have been noted and proved histologically on numerous occasions, and this is the main reason for my continuing to use the trans-sternal approach.

M J LANGE
Royal Free Hospital, London NW3

Diagnosis of gastric cancer

SIR,—The article by Dr A W Segal and others (21 June, p 669) emphasises the poor diagnostic yield of direct vision gastric biopsy in relation to gastric carcinomas. The result of only 70% biopsy confirmation of carcinoma is by no means in keeping with experience in other centres. Kasugai reports a 92.8% positive biopsy correlation in 751 proved gastric carcinomas.1

In all but four of 130 gastric carcinomas examined by endoscopy at this hospital in just over four years the diagnosis was confirmed by biopsy evidence. Two of the patients with the false-negative biopsy results were recognised by the endoscopist to have advanced carcinoma. There were no false-positive biopsies. We took 8-12 bites routinely of all doubtful or suspicious ulcers, using the Olympus GIF or JFB instruments. Our current policy is that surgery for cancer is not performed unless a positive biopsy report is obtained. However, if a lesion is suspected of being malignant endoscopy and biopsy are repeated until radiology, endoscopy, and biopsy findings correlate.

Dr Segal and his colleagues do not refer to the problem of the diagnosis of early gastric cancer, which is so well recognised by Japanese workers.2

Despite the falling standardised mortality rate in Australia for gastric cancer the recognition of these early lesions does much to increase survival figures. In our experience with early gastric cancer the reliance on biopsy and its interpretation is paramount and the overall value of direct-vision gastric biopsy cannot be over-emphasised.

G S NAGY
P R GREEN
D I FEVRE
Gastroenterology Unit, Royal North Shore Hospital, Sydney, New South Wales

Paradoxical effect of pindolol

SIR,—Dr Hendrika J Waal-Manning and F O Simpson (19 July, p 155) report on nine cases among 200 hypertensive patients whose blood pressure (BP) fell when the dose of pindolol was reduced. From our experience with pindolol in hypertension the incidence of this so-called ‘paradoxical’ effect may be more general than is suggested.

We have recently carried out a controlled study,1 in which a reduction of the pindolol dosage from about 30 mg daily to about 20 mg daily consistently gave a further reduction in blood pressure.

Of 38 patients with mild hypertension (WHO grade 1) with a diastolic BP of 100-129 mm Hg, 20 were treated with pindolol and 18 with propranolol for 14 weeks after an initial placebo period of four weeks. The patients were examined six times (initially, after the placebo period (visit 2), after a pretreatment period, after four weeks' treatment with the full dosage of pindolol (29 mg daily) or propranolol (232 mg daily), and four weeks' further treatment with an individually adjusted dose of pindolol (average 29 mg daily) or propranolol (average 241 mg daily) (visit 5), and finally after a further four weeks' treatment during which the individual doses were reduced by one-third by the elimination of the midday dose so that patients received medication in the morning and evening only (visit 6).

The table shows how the BP changed between visits. At visit 5 the BP reductions on pindolol and propranolol were similar; further reductions followed on pindolol treatment when the dose was lowered and given only twice daily during the last four-week period. The results with propranolol were somewhat different: the systolic, diastolic, and mean pressure decreased up to visit 5 but increased again after dosage reduction and the change to twice-daily administration.

PER BJERLE
K-A JACOBSSON
G AGERT
Department of Clinical Physiology, University of Umeå, Umeå, Sweden

Serum cholesterol and enzyme-inducing agents

SIR,—We read with interest the report by Dr Risto Pelkonen and others (11 October, p 85) of increased serum cholesterol levels in patients receiving phenytoin. We have recently completed an investigation of the effects of phenobarbitone on serum lipids in healthy young volunteers (the results of which have been submitted for publication elsewhere). We similarly found a significant increase in the level of total serum cholesterol occurring within three weeks, which was entirely accounted for by a rise in low density lipoprotein cholesterol. Total serum triglycerides and very low density lipoprotein triglycerides were not altered, although a significant rise in low density lipoprotein triglycerides did occur. Evidence that drug-metabolising enzymes were induced was provided by a considerable increase in antipyrine clearance.

Microsomal enzyme induction, an effect of both phenobarbitone and phenytoin, would be a possible mechanism for the rise of serum cholesterol, since the rate-limiting enzyme for cholesterol biosynthesis, 3-hydroxy- 3-methylglutaryl-CoA reductase, is microsomaly located.1 Increased hepatic and intestinal cholesterol synthesis has been produced experimentally in phenobarbitone-treated animals.2

Raised levels of serum cholesterol have previously been shown in persons receiving phenobarbitone,3 in children on anticonvulsant therapy, and in a patient undergoing medical treatment with phenobarbitone for gallstones.4 Therefore we would agree that a rise in serum cholesterol is a

*Two patients were excluded since they did not follow the dosage instructions.